Akero Therapeutics, Inc. — Director's Dealing 2024

Jul 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2024-07-16

Reporting Person: White William Richard (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-07-16	Common Stock	M	29803	$7.009	Acquired	76602	Direct
2024-07-16	Common Stock	S	29803	$28.045	Disposed	46799	Direct
2024-07-16	Common Stock	S	5008	$28.045	Disposed	41791	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-07-16	Stock Option (Right to Buy)	$7.009	M	29803	Disposed	2029-04-04	Common Stock (29803)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 13, 2024, previously adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.000 to $28.125, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The options are vested and currently exercisable.